About Ampio Pharmaceuticals (NASDAQ:AMPE)
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AMPE
- CUSIP: N/A
- Web: ampiopharma.com/
- Market Cap: $74.37 million
- Outstanding Shares: 68,232,000
- 50 Day Moving Avg: $0.72
- 200 Day Moving Avg: $0.63
- 52 Week Range: $0.38 - $1.34
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.74
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.05 per share
- Price / Book: 21.80
- EBITDA: ($12,770,000.00)
- Return on Equity: -239.01%
- Return on Assets: -87.54%
- Average Volume: 525,363 shs.
- Short Ratio: 15.47
Frequently Asked Questions for Ampio Pharmaceuticals (NASDAQ:AMPE)
What is Ampio Pharmaceuticals' stock symbol?
Ampio Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPE."
Who are some of Ampio Pharmaceuticals' key competitors?
Some companies that are related to Ampio Pharmaceuticals include Cempra (CEMP), Verastem (VSTM), XBiotech (XBIT), Summit Therapeutics PLC (SMMT), Cellular Biomedicine Group (CBMG), Immune Design Corp. (IMDZ), Verona Pharma Plc (VRP), ImmuPharma PLC (IMM), Cidara Therapeutics (CDTX), MaxCyte (MXCT), Aldeyra Therapeutics (ALDX), Axsome Therapeutics (AXSM), Synthetic Biologics (SYN), Dicerna Pharmaceuticals (DRNA), DURECT Corporation (DRRX), Summit Therapeutics PLC (SUMM), ProQR Therapeutics N.V. (PRQR) and Motif Bio PLC (MTFB).
Who are Ampio Pharmaceuticals' key executives?
Ampio Pharmaceuticals' management team includes the folowing people:
- Michael Macaluso, Chairman of the Board, Chief Executive Officer
- Thomas E. Chilcott III, Chief Financial Officer
- Holli Cherevka, Chief Operating Officer
- David Bar-Or M.D., Chief Scientific Officer, Director
- Gregory A. Gould CPA, Treasurer, Secretary
- Vaughan Lennox Clift M.D., Chief Regulatory Affairs Officer
- Philip H. Coelho M.D., Independent Director
- Richard B. Giles, Independent Director
- David R. Stevens Ph.D., Independent Director
How do I buy Ampio Pharmaceuticals stock?
Shares of Ampio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ampio Pharmaceuticals' stock price today?
MarketBeat Community Rating for Ampio Pharmaceuticals (NASDAQ AMPE)MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ampio Pharmaceuticals stock can currently be purchased for approximately $1.09.
Consensus Ratings for Ampio Pharmaceuticals (NASDAQ:AMPE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Ampio Pharmaceuticals (NASDAQ:AMPE)
Analysts' Ratings History for Ampio Pharmaceuticals (NASDAQ:AMPE)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ampio Pharmaceuticals (NASDAQ:AMPE)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Ampio Pharmaceuticals (NASDAQ:AMPE)
Current Year EPS Consensus Estimate: $-0.61 EPS
Next Year EPS Consensus Estimate: $-0.19 EPS
Dividend History for Ampio Pharmaceuticals (NASDAQ:AMPE)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Ampio Pharmaceuticals (NASDAQ:AMPE)
Latest Headlines for Ampio Pharmaceuticals (NASDAQ:AMPE)
Loading headlines, please wait.
Ampio Pharmaceuticals (AMPE) Chart for Sunday, October, 22, 2017